534 related articles for article (PubMed ID: 18834911)
1. Comparison of plaque reduction neutralisation test (PRNT) and measles virus-specific IgG ELISA for assessing immunogenicity of measles vaccination.
Cohen BJ; Doblas D; Andrews N
Vaccine; 2008 Nov; 26(50):6392-7. PubMed ID: 18834911
[TBL] [Abstract][Full Text] [Related]
2. Measles immunity testing: comparison of two measles IgG ELISAs with plaque reduction neutralisation assay.
Cohen BJ; Parry RP; Doblas D; Samuel D; Warrener L; Andrews N; Brown D
J Virol Methods; 2006 Feb; 131(2):209-12. PubMed ID: 16188328
[TBL] [Abstract][Full Text] [Related]
3. Plaque reduction neutralization test for measles antibodies: Description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination.
Cohen BJ; Audet S; Andrews N; Beeler J;
Vaccine; 2007 Dec; 26(1):59-66. PubMed ID: 18063236
[TBL] [Abstract][Full Text] [Related]
4. Persistence of vaccine-induced antibody to measles 26-33 years after vaccination.
Dine MS; Hutchins SS; Thomas A; Williams I; Bellini WJ; Redd SC
J Infect Dis; 2004 May; 189 Suppl 1():S123-30. PubMed ID: 15106101
[TBL] [Abstract][Full Text] [Related]
5. Development and evaluation of an automatable focus reduction neutralisation test for the detection of measles virus antibodies using imaging analysis.
Terletskaia-Ladwig E; Enders G; Meier S; Dietz K; Enders M
J Virol Methods; 2011 Dec; 178(1-2):124-8. PubMed ID: 21939689
[TBL] [Abstract][Full Text] [Related]
6. [The study of countermeasures on measles control in infants].
Wang L; Sun L; Jiang Z; Kang S; Liu Y; Jiang X
Zhonghua Liu Xing Bing Xue Za Zhi; 2001 Feb; 22(1):49-50. PubMed ID: 11860845
[TBL] [Abstract][Full Text] [Related]
7. Measles antibodies and response to vaccination in children aged less than 14 months: implications for age of vaccination.
Borràs E; Urbiztondo L; Costa J; Batalla J; Torner N; Plasencia A; Salleras L; Domínguez À;
Epidemiol Infect; 2012 Sep; 140(9):1599-606. PubMed ID: 22074684
[TBL] [Abstract][Full Text] [Related]
8. [Comparison and evaluation of enzyme-linked immunization assay kits with plague reduction neutralization test for detection of measles IgG antibody].
Mao NY; Zhu Z; Jiang XH
Zhongguo Yi Miao He Mian Yi; 2009 Jun; 15(3):215-8. PubMed ID: 20084884
[TBL] [Abstract][Full Text] [Related]
9. Seroconversion after measles vaccination at nine and fifteen months of age.
Işik N; Uzel N; Gökçay G; Kiliç A; Yilmaz G; Sadikoğlu B; Diri S
Pediatr Infect Dis J; 2003 Aug; 22(8):691-5. PubMed ID: 12913768
[TBL] [Abstract][Full Text] [Related]
10. Optimal age for measles vaccination.
Vidyashankar C
J Indian Med Assoc; 2002 Jan; 100(1):24-6. PubMed ID: 12206338
[TBL] [Abstract][Full Text] [Related]
11. Impact of revaccinating children who initially received measles vaccine before 10 months of age.
Stetler HC; Orenstein WA; Bernier RH; Herrmann KL; Sirotkin B; Hopfensperger D; Schuh R; Albrecht P; Lievens AW; Brunell PA
Pediatrics; 1986 Apr; 77(4):471-6. PubMed ID: 3960615
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of measles revaccination among school-entry-aged children.
Watson JC; Pearson JA; Markowitz LE; Baughman AL; Erdman DD; Bellini WJ; Baron RC; Fleming DW
Pediatrics; 1996 May; 97(5):613-8. PubMed ID: 8628596
[TBL] [Abstract][Full Text] [Related]
13. [Study on the immunization effect of measles vaccine by capture-EIA].
Fang H
Zhonghua Liu Xing Bing Xue Za Zhi; 1992 Oct; 13(5):297-9. PubMed ID: 1300252
[TBL] [Abstract][Full Text] [Related]
14. Measles cases in highly vaccinated population of Novosibirsk, Russia, 2000-2005.
Atrasheuskaya AV; Kulak MV; Neverov AA; Rubin S; Ignatyev GM
Vaccine; 2008 Apr; 26(17):2111-8. PubMed ID: 18343536
[TBL] [Abstract][Full Text] [Related]
15. [Measles and mumps antibody concentrations in newborns and their mothers--follow up first year of life].
Hohendahl J; Peters N; Hüttermann U; Rieger C
Klin Padiatr; 2006; 218(4):213-20. PubMed ID: 16819702
[TBL] [Abstract][Full Text] [Related]
16. Humoral immunity and correlation between ELISA, hemagglutination inhibition, and neutralization tests after vaccination against tick-borne encephalitis virus in children.
Venturi G; Mel R; Marchi A; Mancuso S; Russino F; Pra GD; Papa N; Bertiato G; Fiorentini C; Ciufolini MG
J Virol Methods; 2006 Jun; 134(1-2):136-9. PubMed ID: 16458368
[TBL] [Abstract][Full Text] [Related]
17. Protection against challenge with measles virus (MV) in infant macaques by an MV DNA vaccine administered in the presence of neutralizing antibody.
Premenko-Lanier M; Rota PA; Rhodes GH; Bellini WJ; McChesney MB
J Infect Dis; 2004 Jun; 189(11):2064-71. PubMed ID: 15143474
[TBL] [Abstract][Full Text] [Related]
18. [Comparison between the plaque reduction neutralization test and the hemagglutination inhibition test in determination of human anti-measles antibodies].
Kong J; Guo SH; Ze WY
Zhonghua Liu Xing Bing Xue Za Zhi; 1996 Apr; 17(2):105-7. PubMed ID: 8758407
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of standard dose Edmonston-Zagreb measles vaccine in highland Papua New Guinean children from four months of age.
Rogers S; Sanders RC; Alpers MP
J Trop Med Hyg; 1991 Apr; 94(2):88-91. PubMed ID: 2023293
[TBL] [Abstract][Full Text] [Related]
20. Immunoglobulin G subclass profile of antimeasles response in vaccinated children and in adults with measles history.
Toptygina AP; Pukhalsky AL; Alioshkin VA
Clin Diagn Lab Immunol; 2005 Jul; 12(7):845-7. PubMed ID: 16002633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
